|
As Chairman and CEO Candace Kendle has provided the overall vision and strategy to grow Kendle into a leading global CRO. Under her leadership Kendle has advanced to become the fourth-largest provider of Phase II-IV development services worldwide with more than 3 000 associates and operations across North America Europe Asia/Pacific Latin America and Africa. Kendle will mark its 10th year as a publicly-held company on Aug. 22 2007.
In the thriving and increasingly competitive e-clinical trials marketplace Dr. Kendle's focus has been on positioning the company to compete at the highest level for large global clinical development programs. In support of this goal she led Kendle through a strategic transformation in 2006 with the acquisition of the Phase II-IV Clinical Services business of Charles River Laboratories increasing the company's size by 50 percent and strengthening its position as one of the leading global players in the CRO industry. As a result Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites and "Best Contract Research Organization" in November 2006 by an independent panel for Scrip World Pharmaceutical News.
Dr. Kendle is a recognized leader in the CRO industry. She is a founding member and Immediate Past Chair (2006) of the Association of Clinical Research Organizations (ACRO) which fosters continued advancement of medical product development and expedites the introduction of new medicines and new treatments to improve health and save lives.
Dr. Kendle is a member of the Harvard Business School Alumni Association Board and a member of the Committee of 200 an organization of preeminent women entrepreneurs and corporate leaders. Dr. Kendle also serves as a director of the H.J. Heinz Company. She has received numerous civic financial and pharmaceutical industry leadership awards.Prior to founding the company Dr. Kendle held senior faculty positions in the pharmaceutical programs of several leading institutions. More recently she has played a key role in the development of the master of science program in global drug development at the University of Cincinnati. | 